These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 28132702)

  • 1. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychoactive medications and disengagement from office based opioid treatment (obot) with buprenorphine.
    Weinstein ZM; Cheng DM; Quinn E; Hui D; Kim H; Gryczynski G; Samet JH
    Drug Alcohol Depend; 2017 Jan; 170():9-16. PubMed ID: 27865152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 5. Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study.
    Geist ML; Radick AC; Tsui JI; Blalock KL; Adwell A; Tamru E; Connolly NC; James JR
    Addict Sci Clin Pract; 2023 May; 18(1):33. PubMed ID: 37231486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking patients with buprenorphine treatment in primary care: Predictors of engagement.
    Simon CB; Tsui JI; Merrill JO; Adwell A; Tamru E; Klein JW
    Drug Alcohol Depend; 2017 Dec; 181():58-62. PubMed ID: 29035705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staff Attitudes toward Buprenorphine before and after Implementation of an Office-Based Opioid Treatment Program in an Urban Teaching Clinic.
    James JR; Marolf M; Klein JW; Blalock KL; Merrill JO; Tsui JI
    Subst Use Misuse; 2021; 56(11):1569-1575. PubMed ID: 34282999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
    Carey KJ; Huang W; Linas BP; Tsui JI
    J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "I'm on the Right Path": Exploring 1-Month Retention in a Homeless-Tailored Outpatient-Based Opioid Treatment Program.
    Fine DR; Critchley N; Hart K; Joyce A; Sporn N; Gaeta J; Wright J; Baggett TP; Kruse G
    Subst Use Addctn J; 2024 Apr; 45(2):268-277. PubMed ID: 38258838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
    Haddad MS; Zelenev A; Altice FL
    J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Retention in an Outpatient Behavioral Health Clinic With Buprenorphine.
    Montalvo C; Stankiewicz B; Brochier A; Henderson DC; Borba CPC
    Am J Addict; 2019 Sep; 28(5):339-346. PubMed ID: 31066985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year Retention Rates With Office-based Treatment of Buprenorphine for Opioid Use Disorder in a Private Family Medicine Practice.
    Cope K; DeMicco J; Salib J; Michael M; Yakoub P; Daoud K; Cope R
    J Addict Med; 2022 Nov-Dec 01; 16(6):716-721. PubMed ID: 35913992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Buprenorphine Receipt and Retention for Opioid Use Disorder Following an Initiative to Increase Access in Primary Care.
    Hawkins EJ; Malte CA; Hagedorn HJ; Gordon AJ; Williams EC; Trim RS; Blanchard BE; Lott A; Danner AN; Saxon AJ
    J Addict Med; 2024 May-Jun 01; 18(3):240-247. PubMed ID: 38329814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors.
    Tesema L; Marshall J; Hathaway R; Pham C; Clarke C; Bergeron G; Yeh J; Soliman M; McCormick D
    Subst Abus; 2018; 39(4):434-440. PubMed ID: 29513136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program.
    Jakubowski A; Lu T; DiRenno F; Jadow B; Giovanniello A; Nahvi S; Cunningham C; Fox A
    J Subst Abuse Treat; 2020 Dec; 119():108140. PubMed ID: 33138925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.